EB1007

EB1007 is a biosimilar candidate currently in preclinical development by Eden Biologics (formerly known as JHL Biotech) for the treatment of oncology indications. As part of the company's biosimilar pipeline, EB1007 is designed to be highly similar to an existing, approved reference biological product. While Eden Biologics has disclosed the targets for other pipeline assets (such as denosumab and pembrolizumab biosimilars), the specific reference product and molecular target for EB1007 have not been publicly identified. The program is currently focused on establishing analytical and functional similarity to its reference biologic through preclinical studies.